Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The peptide-based vaccine induces a t cell-dependent response
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Sputnik Light is the first component of Sputnik V
Subscribe To Our Newsletter & Stay Updated
